AGN – Positive Migraine Data out earlier than expected!!!!



11-Jun-18 08:03 ET


Allergan announces positive results from CGP-MD-01 (170.35) 

All active treatment arms of atogepant met the primary endpoint across all doses and dose regimens, with a statistically significant reduction from baseline in monthly migraine/probable migraine (MPM) headache days in patients with episodic migraine treated with atogepant compared with placebo for 12 weeks. Atogepant is Allergan’s second orally-administered investigational calcitonin gene-related peptide (CGRP) receptor antagonist in development for migraine prevention. Atogepant follows ubrogepant, Allergan’s first oral investigational CGRP antagonist for the acute treatment of migraine, which reported two positive Phase 3 pivotal trial results earlier this year.

  • Allergan will continue with its phase 3 program for atogepant following discussions with regulatory authorities.

Click here to read the full comment.

Portfolio Ticker Matches:  AGN